Open Access
Open access
mAbs, volume 12, issue 1

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Marco Tuccori 1, 2
Sara Ferraro 2
Irma Convertino 2
Emiliano Cappello 2
Giulia Valdiserra 2
Corrado Blandizzi 1, 2
Fabrizio Maggi 3
Daniele Focosi 4
Publication typeJournal Article
Publication date2020-01-01
Journal: mAbs
Quartile SCImago
Q1
Quartile WOS
Q2
Impact factor5.3
ISSN19420862, 19420870
Immunology
Immunology and Allergy

Top-30

Citations by journals

1
2
3
4
5
6
Vaccines
6 publications, 4.72%
Viruses
5 publications, 3.94%
Scientific Reports
5 publications, 3.94%
Nature Communications
3 publications, 2.36%
Signal Transduction and Targeted Therapy
3 publications, 2.36%
mAbs
3 publications, 2.36%
Immunotherapy
2 publications, 1.57%
PLoS ONE
2 publications, 1.57%
Frontiers in Immunology
2 publications, 1.57%
Journal of Biomedical Science
2 publications, 1.57%
Computational and Structural Biotechnology Journal
2 publications, 1.57%
International Immunopharmacology
2 publications, 1.57%
The Lancet Infectious Diseases
2 publications, 1.57%
Expert Opinion on Drug Discovery
2 publications, 1.57%
Science advances
2 publications, 1.57%
Science Translational Medicine
1 publication, 0.79%
AIDS Research and Human Retroviruses
1 publication, 0.79%
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
1 publication, 0.79%
Biochemical Society Transactions
1 publication, 0.79%
Molecular Medicine Reports
1 publication, 0.79%
Clinical Nurse Specialist
1 publication, 0.79%
Infectious Diseases in Clinical Practice
1 publication, 0.79%
World Journal of Virology
1 publication, 0.79%
Internal Medicine
1 publication, 0.79%
Inquiry (United States)
1 publication, 0.79%
Life
1 publication, 0.79%
Antioxidants
1 publication, 0.79%
International Journal of Molecular Sciences
1 publication, 0.79%
Pathogens
1 publication, 0.79%
1
2
3
4
5
6

Citations by publishers

5
10
15
20
25
Springer Nature
24 publications, 18.9%
Elsevier
24 publications, 18.9%
Multidisciplinary Digital Publishing Institute (MDPI)
20 publications, 15.75%
Cold Spring Harbor Laboratory
13 publications, 10.24%
Wiley
6 publications, 4.72%
Taylor & Francis
5 publications, 3.94%
American Association for the Advancement of Science (AAAS)
4 publications, 3.15%
Frontiers Media S.A.
4 publications, 3.15%
Public Library of Science (PLoS)
3 publications, 2.36%
American Society for Microbiology
3 publications, 2.36%
Future Medicine
2 publications, 1.57%
Mary Ann Liebert
2 publications, 1.57%
Wolters Kluwer Health
2 publications, 1.57%
Portland Press
1 publication, 0.79%
Spandidos Publications
1 publication, 0.79%
Baishideng Publishing Group
1 publication, 0.79%
Japanese Society of Internal Medicine
1 publication, 0.79%
SAGE
1 publication, 0.79%
International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)
1 publication, 0.79%
Dove Medical Press
1 publication, 0.79%
Oxford University Press
1 publication, 0.79%
Hindawi Limited
1 publication, 0.79%
Acta Naturae Ltd
1 publication, 0.79%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 0.79%
Pharmaceutical Society of Japan
1 publication, 0.79%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.79%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Tuccori M. et al. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline // mAbs. 2020. Vol. 12. No. 1.
GOST all authors (up to 50) Copy
Tuccori M., Ferraro S., Convertino I., Cappello E., Valdiserra G., Blandizzi C., Maggi F., Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline // mAbs. 2020. Vol. 12. No. 1.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1080/19420862.2020.1854149
UR - https://www.tandfonline.com/doi/full/10.1080/19420862.2020.1854149
TI - Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
T2 - mAbs
AU - Tuccori, Marco
AU - Ferraro, Sara
AU - Convertino, Irma
AU - Cappello, Emiliano
AU - Valdiserra, Giulia
AU - Blandizzi, Corrado
AU - Maggi, Fabrizio
AU - Focosi, Daniele
PY - 2020
DA - 2020/01/01 00:00:00
PB - Taylor & Francis
IS - 1
VL - 12
PMID - 33319649
SN - 1942-0862
SN - 1942-0870
ER -
BibTex
Cite this
BibTex Copy
@article{2020_Tuccori,
author = {Marco Tuccori and Sara Ferraro and Irma Convertino and Emiliano Cappello and Giulia Valdiserra and Corrado Blandizzi and Fabrizio Maggi and Daniele Focosi},
title = {Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline},
journal = {mAbs},
year = {2020},
volume = {12},
publisher = {Taylor & Francis},
month = {jan},
url = {https://www.tandfonline.com/doi/full/10.1080/19420862.2020.1854149},
number = {1},
doi = {10.1080/19420862.2020.1854149}
}
Found error?